增骨Ⅰ、Ⅱ、Ⅲ号序贯疗法防治骨质疏松症的骨组织形态学计量分析  

THE PREVENTION AND TREATMENT OF OSTEOPOROSIS BY SEQUENTIAL THERAPY WITH “ZENGGU” Ⅰ, Ⅱ and Ⅲ: A Histomorphometrical Analysis of the Bone

作　　者：魏玉玲[1] 郭邦富[1] 梁克玉[1] 

机构地区：[1]湖北中医学院附属医院

出　　处：《中医正骨》1999年第7期8-9,共2页The Journal of Traditional Chinese Orthopedics and Traumatology

摘　　要：为探讨增骨Ⅰ、Ⅱ、Ⅲ号序贯疗法治疗骨质疏松症的机理，进行了骨组织形态学计量分析。采用６０只１０月龄Ｗｉｓｔａｒ大鼠，随机分成６组（正常、西药、序贯预防、序贯治疗、验方及模型组）。除正常组外，其余大鼠均行双侧卵巢切除。在去势后６个月处死全部动物，制成不脱钙骨切片进行组织形态学计量分析。结果显示序贯预防组大鼠的骨量最多，与正常组无差异（Ｐ＞０．０５）。序贯治疗组大鼠的骨量与验方组比较有明显增加（Ｐ＜０．０５）；与西药组比较虽无显著差异（Ｐ＞０．０５），但后者并发症多。本实验研究证明增骨Ⅰ、Ⅱ、Ⅲ号序贯疗法能建立骨重建正性平衡，并且能有效地防治骨质疏松症。Sixty Wistar rats aged 10 months were randomly divided into six groups: the normal, Western medicine (WM), sequential prevented (SP), sequential treated (ST), proved recipe (PR) and modelled groups. The rats of all the groups but the normal one were ovariectomized bilaterally. Six months after ovariectomy, the 60 rats were killed and the non calcified osseous sections made from them were analysed by histomorphometry as to explore the mechanism of the treatment of osteoporosis by sequential therapy with “ZENGGU” (STZ) Ⅰ, Ⅱ and Ⅲ. The results showed the greatest bone quantity in SP group with no difference from the normal group (P > 0.05); significantly increased bone quantity in ST group in comparison with PR group (P < 0.05); no marked difference of ST group from WM group (P > 0.05) but the latter had many complications. This study proved that STZ Ⅰ, Ⅱ and Ⅲ could set up the positive balance of bone reconstruction, prevent and treat osteoporosis effectively.

关 键 词：骨质疏松 中医药疗法 序贯疗法 骨重建 

分 类 号：R274.91[医药卫生—中西医结合]